Most T-cell lymphomas are CD4+/CD45+ high-grade lymphomas (lymphoblastic or peripheral T-cell lymphomas) expressing low II MHC with an aggressive disease course, regardless of the treatment regimen (median survival of 159 days). This evidence concerns the gene CD4 and lymphoma.